CARDIFF ONCOLOGY, INC. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- CARDIFF ONCOLOGY, INC. stock issued during period, value, new issues for the quarter ending 2026-06-30 was $148.00.
- CARDIFF ONCOLOGY, INC. stock issued during period, value, new issues for the quarter ending 2024-09-30 was $7.43M.
- CARDIFF ONCOLOGY, INC. stock issued during period, value, new issues for the quarter ending 2024-06-30 was $1.80M.
- CARDIFF ONCOLOGY, INC. stock issued during period, value, new issues for the quarter ending 2021-06-30 was $19.23M.
- CARDIFF ONCOLOGY, INC. stock issued during period, value, new issues for fiscal 2024 was $53.41M.
- CARDIFF ONCOLOGY, INC. stock issued during period, value, new issues for fiscal 2018 was $4.39M, a 59.61% decline from fiscal 2017.
- CARDIFF ONCOLOGY, INC. stock issued during period, value, new issues for fiscal 2017 was $10.86M, a 375.24% increase from fiscal 2016.
- CARDIFF ONCOLOGY, INC. stock issued during period, value, new issues for fiscal 2016 was $2.29M, a 96.27% decline from fiscal 2015.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2026-06-30 | $148.00 10-Q · filed 2026-08-11 | |
| 2024-12-31 | $53.41M 10-K · filed 2026-02-24 | |
| 2024-09-30 | $7.43M 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $1.80M 10-Q · filed 2025-11-06 | |
| 2021-06-30 | $19.23M 10-Q · filed 2022-11-03 | |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $4.39M 10-K · filed 2020-02-27 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | |
| 2018-06-30 | $4.39M 10-Q · filed 2019-11-07 | |
| 2017-12-31 | $10.86M 10-K · filed 2019-03-06 | |
| 2016-12-31 | $2.29M 10-K · filed 2018-02-26 | |
| 2015-12-31 | $61.22M 10-K · filed 2017-03-15 | |
| 2013-12-31 | -$67.74K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-10 | $18.83M 10-K · filed 2016-03-10 |
| 2003-01-31 | $3.40K 10-Q · filed 2012-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B |